From the publishers of JADPRO

DLBCL Resource Center


Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We encourage you to take a look around at all the cutting-edge information, education, research, and other resources we’ve curated to empower your practice in this disease space. If you have any feedback or questions, please contact

Katherine L. Byar, MSN, APN, BC, BMTCN®️®️®️
Oncology/ Hematology Nurse Practitioner
Fred & Pamela Buffett Cancer Center
Nebraska Medicine
Omaha, Nebraska

News & Literature Highlights

Current Oncology

Ibrutinib plus RCHOP versus RCHOP only in young patients with activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL): A cost-effectiveness analysis

British Journal of Haematology

The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline

Future Oncology

Treatment patterns and costs among US patients with diffuse large B-cell lymphoma not treated with 2L stem cell transplantation

2023 American Society of Hematology Annual Meeting Abstract

Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study

2023 American Society of Hematology Annual Meeting Abstract

Subcutaneous epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma from EPCORE NHL-5

2023 American Society of Hematology Annual Meeting Abstract

Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume


Clonal relationship and mutation analysis in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with diffuse large B-cell lymphoma

International Journal of Cancer

Transformation to diffuse large B-cell lymphoma and its impact on survival in patients with marginal zone lymphoma: A population-based study

Frontiers in Oncology

Hepatitis B virus and B-cell lymphoma: Evidence, unmet need, clinical impact, and opportunities

Clinical Lymphoma, Myeloma, and Leukemia

ABCL-647 The outcome of tisagenlecleucel (tisa-cel) CD-19 CAR-T cell therapy in NHL relapsed/refractory beyond second line of therapy, single-center data